Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.

ABSTRACT:

Objective

Coagulopathy is one of the characteristics observed in critically ill patients with coronavirus disease 2019 (COVID-19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, though their role in COVID-19 remains unclear. This study was undertaken to determine the prevalence and characteristics of aPLs in patients with COVID-19.

Methods

Sera collected from 66 COVID-19 patients who were critically ill and 13 COVID-19 patients who were not critically ill were tested by chemiluminescence immunoassay for anticardiolipin antibodies (aCLs), anti-β₂ -glycoprotein I (anti-β₂ GPI) (IgG, IgM, and IgA), and IgG anti-β₂ GPI-domain 1 (anti-β₂ GPI-D1) and IgM and IgG anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies

SUBMITTER: Xiao M 

PROVIDER: S-EPMC7361932 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature